液体活检已成为一种有前途的非侵入性癌症诊断策略，能够检测各种循环生物标志物，包括循环肿瘤细胞（CTC）、循环肿瘤核酸（ctNA）、循环肿瘤衍生的小细胞外囊泡（sEV）、和循环蛋白质。表面增强拉曼散射 (SERS) 生物传感器为这些生物标志物提供灵敏且特异的检测方法，彻底改变了液体活检技术。本综述全面探讨了基于 SERS 的生物传感器在癌症诊断液体活检中识别和分析各种循环生物标志物（包括 CTC、ctNA、sEV 和蛋白质）的应用。讨论涵盖了各种SERS生物传感器平台，包括无标记SERS测定、基于磁珠的SERS测定、基于微流体装置的SERS系统和基于纸的SERS测定，每个平台都展示了增强灵敏度和特异性的独特能力。液体活检癌症生物标志物的检测。本综述严格评估了 SERS 生物传感器在癌症诊断液体活检中的优势、局限性和未来方向。© 2024。作者。

Liquid biopsy has emerged as a promising non-invasive strategy for cancer diagnosis, enabling the detection of various circulating biomarkers, including circulating tumor cells (CTCs), circulating tumor nucleic acids (ctNAs), circulating tumor-derived small extracellular vesicles (sEVs), and circulating proteins. Surface-enhanced Raman scattering (SERS) biosensors have revolutionized liquid biopsy by offering sensitive and specific detection methodologies for these biomarkers. This review comprehensively examines the application of SERS-based biosensors for identification and analysis of various circulating biomarkers including CTCs, ctNAs, sEVs and proteins in liquid biopsy for cancer diagnosis. The discussion encompasses a diverse range of SERS biosensor platforms, including label-free SERS assay, magnetic bead-based SERS assay, microfluidic device-based SERS system, and paper-based SERS assay, each demonstrating unique capabilities in enhancing the sensitivity and specificity for detection of liquid biopsy cancer biomarkers. This review critically assesses the strengths, limitations, and future directions of SERS biosensors in liquid biopsy for cancer diagnosis.© 2024. The Author(s).